The ABPI welcomes the government’s recognition of investing in science, research and development, and its commitment to creating an industrial strategy which supports science and innovation.
Key Autumn Statement announcements include:
As the UK's biggest investor in research and development at £4.2 billion and 20 per cent of total research and development expenditure – more than double that of any other sector - we look forward to further detail on the investment bound for medical and pharmaceutical research and development.
ABPI, Chief Executive, Mike Thompson, said:
## ENDS ##
ABPI Press Office
Telephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441
Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.